Back to School: How biopharma can reboot drug development. Access exclusive analysis here

1013 Gossamer asthma
BioCentury & Getty Images

Product Development

Gossamer takes a nosedive on Phase II results, but sees path forward in asthma

Oct 13, 2020 | 9:10 PM GMT

The failure of Gossamer’s lead program in two Phase II trials continues to sow doubts about the efficacy of drug candidates targeting PTGDR2, but the company believes further analysis of one study’s data still points to a path forward in asthma, one of the trials’ two

Read the full 732 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers